Which oral dopamine agonist can be used to suppress prolactin and stop lactation?

Oral Dopamine Agonist for Lactation Suppression

Cabergoline is the preferred oral dopamine agonist for stopping lactation, given as a single 1 mg dose, which is superior to bromocriptine in terms of tolerability, ease of use, and lower rates of rebound breast activity. 1

Primary Recommendation

The most recent 2025 BJOG guideline provides Level 1A evidence that cabergoline should be advised for lactation suppression based on a double-blind RCT of 272 women. 1 This study demonstrated that:

• Single dose of cabergoline (1 mg) was as effective as bromocriptine (2.5 mg twice daily for 14 days)
• Cabergoline was simpler to use (one dose vs. 14 days of treatment)
• Significantly lower rates of rebound breast activity
• Fewer adverse events compared to bromocriptine

Alternative Option: Bromocriptine

While bromocriptine (2.5 mg twice daily for 14 days) has similar effectiveness to cabergoline, it is less preferred due to:

• More complex dosing regimen
• Higher rates of adverse events (72% vs 52% with cabergoline) 2
• Greater rebound breast activity 1

Critical Safety Considerations

Hypertension and Pre-eclampsia

Exercise caution when using dopamine agonists in women with hypertension or pre-eclampsia, as these medications can increase blood pressure and have been associated with intracerebral hemorrhage. 1 However:

• A study of 85 women with late IUFD and hypertensive disorders showed no adverse maternal effects 1
• If using bromocriptine in hypertensive patients, blood pressure monitoring is mandatory, especially during the first days of treatment 1
• Discuss risks versus benefits after trying simple physical measures first (support bra, ice packs, analgesics)

Psychiatric History

Screen carefully for history of psychosis, schizophrenia, bipolar disorder, or postpartum psychosis before prescribing dopamine agonists. 3 While both agents can trigger psychosis in vulnerable individuals, bromocriptine poses a much greater risk than cabergoline. 3 Consider non-pharmacological alternatives in high-risk patients.

Clinical Context

Up to one-third of women experience severe breast pain despite simple measures, making pharmacological suppression clinically important. 1 The 2012 Cochrane review of 62 trials (6,428 women) found that bromocriptine and cabergoline had similar failure rates at day 14 postpartum (RR 1.38,95% CI 0.93–2.05), but the single-dose convenience and superior tolerability profile make cabergoline the clear first choice. 1

Practical Algorithm

1. First-line: Cabergoline 1 mg single oral dose
2. If cabergoline unavailable: Bromocriptine 2.5 mg twice daily for 14 days
3. Before prescribing either agent:
   • Screen for hypertension/pre-eclampsia (weigh risks vs benefits)
   • Screen for psychiatric history (psychosis, bipolar, postpartum psychosis)
   • Monitor blood pressure if using bromocriptine in hypertensive patients
4. Counsel patients about potential adverse effects: gastrointestinal upset, orthostatic hypotension, headache, nasal congestion 4